Compare AbbVie Inc (ABBV) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares International Treasury Bond ETF — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while iShares International Treasury Bond ETF trades at $40.62. The key difference: AbbVie Inc pays a 2.72% dividend while iShares International Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | IGOV | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $43.09 |
52-Week Low | $184.85 | $40.54 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
IGOV trades at $40.75, down 0.71% today, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins. Recent news highlights institutional interest, with DMC Group increasing its stake by 69.5% in Q1 2026, but also notes downside risks from global inflationary pressures affecting its bond holdings.
The outlook remains cautious due to technical bearishness and macroeconomic headwinds, though institutional accumulation may provide some support. Key risks include interest rate sensitivity and geopolitical tensions, warranting close monitoring of earnings and economic indicators for any turnaround signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
